The Center for Metabolism of Infectious Diseases (C4MInD) co-led by John Belisle and Rushika Perera, enables the development of new treatments, preventions, and diagnostics for infectious diseases by resolving host-vector-pathogen-environment interactions at a metabolic level.
Awarded a 2018 Colorado Governor’s Award for High-Impact Research, CDC & CSU principal investigators explain their proof-of-concept study that can be applied to develop an innovative diagnostic test for early Lyme disease.
A team of researchers from the Centers for Disease Control and Prevention and Colorado State University was recognized with one of the 2018 CO-LABS Governor’s Awards for High-Impact Research for identifying a way to distinguish Lyme disease from similar illnesses.
New diagnostic approaches bring hope for patients with debilitating tick-borne illnesses. Led by John Belisle, Colorado State University researchers are using a metabolomic approach to identify small-molecule biomarkers in blood and urine samples to help detect early Lyme disease.
CSU professor John Belisle saw that approaches his team has taken with tuberculosis and leprosy — developing biomarkers or biosignatures for diagnosing a disease or the prognosis for a disease — could be applied to developing a diagnostics for STARI and Lyme disease.
John Belisle, a researcher at Colorado State University, discusses the challenges of finding a way to cure tuberculosis, including the complexities of research going into better understand the disease.
At Colorado State University, one of the world’s largest tuberculosis research programs focuses on developing new drugs, tests and preventative vaccines against this disease, which is a leading cause of death around the globe and resurging with new, drug-resistant strains.